Exchange: NASDAQ·Updated 04:24 PM EDT
CBIO logo

CBIOCrescent Biopharma Inc.

$17.69
$0.52
(2.86%)
Today
Closed $17.69
$0.00
(0.00%)
After Hours
Mkt Cap$487.75M
Vol119,469.00
News
all
press releases
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.read more...
Benzinga
News Placeholder
More News
News Placeholder
HC Wainwright Issues Pessimistic Outlook for CBIO Earnings
Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) - Research analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Crescent Biopharma in a note issued to investors on Monday, May 4th. HC Wainwright analyst M. Kapoor now forecasts that the biopharmaceutic...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Trading Up 8.3% - Here's Why
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 8.3% - Here's Why...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell?
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts
Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened
Crescent Biopharma (NASDAQ:CBIO) Stock Price Passes Above 200 Day Moving Average - What's Next...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above 200-Day Moving Average - Time to Sell?
Crescent Biopharma (NASDAQ:CBIO) Share Price Passes Above 200 Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages
Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and three h...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded Crescent Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright
HC Wainwright decreased their price target on shares of Crescent Biopharma from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Monday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.